PROLOR Biotech files $75M shelf to advance PhII long-acting hGH
This article was originally published in Scrip
Executive Summary
PROLOR Biotech, a clinical-stage company based in Israel, whose focus is using its patented technology to develop longer-acting, proprietary versions of already approved therapeutic proteins ("biobetters"), has filed a shelf registration with the US Securities and Exchange Commission that will allow it to sell up to $75 million of its common stock. The shares are traded on both NYSE-Amex and TASE.